CSL Plasma

CSL Plasma is the plasma-collection business associated with CSL Behring and the broader CSL Limited biotechnology group. Based in Boca Raton, Florida, it operates donor centers that collect human plasma through plasmapheresis. The collected material is tested and supplied within the CSL group for research, quality testing, and the manufacture of plasma-derived therapies. The company is distinct from CSL Behring, which develops and manufactures plasma-derived and recombinant medicines, but the two businesses are closely connected in the supply chain. CSL Plasma's role begins with donor recruitment, screening, collection, and handling of source plasma. This makes the organization part of a vertically integrated model in which a group company gathers a key biological raw material and another group company turns it into treatments for patients. According to reference material describing its operations in 2023, CSL Plasma had approximately 320 collection centers in the United States and 19 additional centers in other countries, including Germany, Hungary, and China. The network employed roughly 17,000 people across medical, phlebotomy, processing, operations, and front-desk roles. Individual centers can require dozens of employees and may be configured with large numbers of donation beds. The company presents plasma donation as a regulated, repeatable process. Donors are screened for health and eligibility requirements, and plasma is separated from other blood components before the remaining components are returned to the donor. CSL Plasma has described the use of the Rika Plasma Donation System at its centers, with a typical collection taking about 25 minutes, although actual times vary by donor and location. In the United States, published eligibility information has included minimum age and weight requirements, government identification, Social Security information, and address verification. Donor eligibility and operating procedures remain subject to local law and medical assessment. Collected plasma can support medicines used in the treatment of hemophilia, primary immunodeficiency, von Willebrand disease, hereditary angioedema, hereditary respiratory disorders, and certain neurological conditions. Plasma-derived products are also relevant to care involving severe burns, cardiac procedures, major trauma, and organ transplantation. Because plasma safety depends on testing and repeat-donation controls, material from a first donation may be held until a subsequent donation is completed and the donor's status can be evaluated. CSL Plasma uses donor-reward and retention programs, including the iGive Rewards loyalty program. It also sponsors Plasma P.A.L.S., a donor-awareness initiative in which donors and people who rely on plasma therapies share experiences. The program was previously known as Adopt-A-Patient and was renamed in 2022. These initiatives position donation as both a compensated activity and a contribution to patients who depend on plasma-derived treatments. The business has also participated in humanitarian and community-relief activities. During the early period of Russia's 2022 invasion of Ukraine, CSL collaborated with humanitarian organizations to support medicines and relief for affected civilians and refugees. It has also worked with the Red Cross on disaster-relief efforts following events such as fires, hurricanes, and tornadoes affecting communities connected with its donation network. CSL Plasma has received regional business recognition, including finalist status in the South Florida Business Journal's 2021 and 2022 Business of the Year Awards. At the same time, the company has faced legal and operational scrutiny involving donor screening, disability access, gender identity, and a reported HIV-testing error. These matters have influenced public discussion of how plasma-collection companies balance medical safety controls, donor access, and equal-treatment obligations.

CSL Plasma developed as the collection and supply-side business supporting the CSL group's plasma-derived medicines activities. Its operating model is based on plasmapheresis: eligible donors give plasma at dedicated centers, where the plasma is separated from the cellular components of blood and prepared for testing, storage, and onward use. The business is closely associated with CSL Behring, a CSL Limited company responsible for plasma-derived and other specialty therapies. The organization is headquartered in Boca Raton, Florida, while its parent group CSL Limited is based in Melbourne, Australia. This structure gives CSL Plasma a North American operating center within an international biotechnology group. Rather than selling a conventional consumer product, the brand manages a distributed healthcare infrastructure made up of donor centers, trained clinical staff, phlebotomists, plasma processors, operations personnel, and donor-service teams. By 2023, reference material described a network of about 320 centers in the United States and 19 more in countries including Germany, Hungary, and China. The same material estimated employment at approximately 17,000 people. Centers may contain many donation beds and are designed to support repeat donations by eligible donors. Donors are screened before collection, and the company publishes requirements concerning age, weight, health status, identification, and other factors. The precise rules can vary by jurisdiction and medical review. The plasma collected by the network is sent to testing laboratories or to CSL Behring for use in manufacturing. The resulting therapies address conditions such as hemophilia, primary immunodeficiency, von Willebrand disease, hereditary angioedema, hereditary respiratory disease, and neurological disorders. Plasma-derived medicines can also be important in emergency and surgical settings, including serious burns, trauma, cardiac procedures, and organ transplantation. The relationship between collection and manufacturing is central to the group's strategy because a dependable supply of qualified plasma is necessary for production planning and patient access. CSL Plasma has used compensation and loyalty tools to encourage repeat participation. New donors may receive a monetary incentive through a reloadable prepaid card, while returning donors can participate in iGive Rewards. The company has also tried to connect donors with the patients who depend on plasma therapies. Its Plasma P.A.L.S. program, renamed from Adopt-A-Patient in September 2022, gives patients an opportunity to share their experiences and helps explain why regular donations matter. Local centers have also conducted community activities, including seasonal events. The brand's community role expanded during humanitarian emergencies. In 2022, at the beginning of the Russian invasion of Ukraine, CSL Plasma partnered with major humanitarian organizations to help provide medicines and support to civilians and refugees. The company had also worked with the Red Cross on disaster-relief activities after fires, hurricanes, and tornadoes affecting areas in which donors and employees lived. Its public profile has included recognition from the South Florida Business Journal, which named CSL Plasma a finalist for its Business of the Year Awards in both 2021 and 2022. The company has nevertheless faced criticism and litigation. In 2020, an Illinois man sued after a preliminary blood test was reported to the U.S. Food and Drug Administration as indicating HIV before the result was confirmed to be a false positive. In 2023, two Minnesota gender-identity cases were resolved through an agreement addressing donor access. That year, an Illinois disability-discrimination case was settled with reported policy changes concerning deaf prospective donors and people who use service animals. In 2024, a Maine center reportedly closed temporarily after a donor incident and the identification of missing equipment. These matters illustrate the operational, medical, and civil-rights issues inherent in running a large plasma-collection network.

• 2024

  Temporary closure of Maine center

  [1]CSL Plasmaen.wikipedia.org

  A Maine facility reportedly closed temporarily after a donor medical incident and the discovery that specified equipment was unavailable.

• 2023

  Reported international collection-center scale

  [1]CSL Plasmaen.wikipedia.org

  Reference material described approximately 320 U.S. centers and 19 additional centers in other countries, with about 17,000 employees.

• 2023

  Minnesota gender-identity cases resolved

  [1]CSL Plasmaen.wikipedia.org

  An agreement resolving two Minnesota cases addressed the exclusion of potential donors based on gender identity.

• 2023

  Illinois disability-access settlement

  [1]CSL Plasmaen.wikipedia.org

  A settlement resolved allegations involving disability discrimination and reportedly led to policy changes for deaf donors and donors requiring service animals.

• 2022

  Plasma P.A.L.S. name introduced

  [1]CSL Plasmaen.wikipedia.org

  The donor-patient awareness program formerly called Adopt-A-Patient was renamed Plasma P.A.L.S., short for Plasma Patients And Life-Savers.

• 2022

  Humanitarian support for Ukraine-related relief

  [1]CSL Plasmaen.wikipedia.org

  CSL Plasma worked with international humanitarian organizations to support medicines and relief for people affected by the war in Ukraine.

• 2022

  Second consecutive South Florida Business of the Year finalist listing

  [1]CSL Plasmaen.wikipedia.org

  The company was again selected as a finalist by the South Florida Business Journal.

• 2021

  South Florida Business of the Year finalist

  [1]CSL Plasmaen.wikipedia.org

  CSL Plasma was recognized as a finalist in the South Florida Business Journal's Business of the Year Awards.

• 2020

  Illinois HIV-testing lawsuit reported

  [1]CSL Plasmaen.wikipedia.org

  CSL Plasma faced a lawsuit after a donor alleged that an HIV result was reported to the FDA before the initial result was confirmed as a false positive.

A large, vertically integrated plasma-collection network emphasizing donor recruitment, medical screening, operational scale, quality control, and supply reliability for plasma-derived therapies.

• Healthcare service

  Plasma collection

  CSL Plasma operates donor centers where qualified individuals undergo screening and plasmapheresis. Plasma is separated from blood and the remaining components are returned to the donor. The collected source plasma is handled under medical and quality procedures and is supplied for testing or for the manufacture of plasma-derived medicines.

• Donor loyalty program

  iGive Rewards

  iGive Rewards is a loyalty program for returning plasma donors. It is part of CSL Plasma's broader donor-retention approach, alongside compensation and center-level service. Specific reward terms can vary and are not detailed here.

• Patient-awareness program · 2022

  Plasma P.A.L.S.

  Plasma P.A.L.S., meaning Plasma Patients And Life-Savers, connects donors with people who rely on plasma therapies. Through patient stories and donor education, the program explains the relationship between a donation and treatment for plasma-dependent conditions. It replaced the Adopt-A-Patient name in 2022.

• 2023

  Gender-identity donor-access litigation

  Two Minnesota cases were resolved through an agreement addressing alleged exclusion of potential donors based on gender identity.

  Source

• 2023

  Disability-discrimination settlement

  An Illinois lawsuit alleged discrimination against disabled potential donors under federal and state civil-rights laws. The settlement reportedly included revised policies for deaf donors and people who use service animals.

  Source

• 2020

  Alleged false-positive HIV notification

  An Illinois lawsuit alleged that CSL Plasma notified the FDA of an HIV-positive blood-test result before the result was confirmed to be a false positive.

  Source

Read more

• 2022Plasma P.A.L.S.

  United States

  The program brings plasma donors and plasma-therapy patients together to share personal experiences and encourage regular donation.

  Outcome. It replaced the earlier Adopt-A-Patient program name and continued CSL Plasma's donor-awareness and patient-storytelling work.

  Source
• 2022Ukraine humanitarian relief

  Ukraine · Europe · International

  CSL Plasma partnered with humanitarian organizations to support medicines and relief for civilians and refugees affected by the Russian invasion of Ukraine.

  Outcome. The initiative contributed to wider CSL humanitarian support during the crisis; the reference material does not quantify its results.

  Source
• Red Cross disaster relief

  United States

  CSL Plasma has partnered with the Red Cross on relief efforts following natural disasters, including fires, hurricanes, and tornadoes affecting donation communities and employees.

  Source

• 2023

  Policy changes following disability-access settlementOther

  Background

  An Illinois lawsuit alleged that the company had not adequately accommodated certain disabled prospective donors.

  Action taken

  CSL Plasma reportedly adopted new policies concerning potential donors who are deaf or require a service animal.

  Aftermath

  The litigation was settled; the reference material does not provide further compliance metrics.

  Source

• 2023

  Agreement addressing gender-identity donor accessOther

  Background

  Two Minnesota court cases concerned alleged barriers to donation for potential donors based on gender identity.

  Action taken

  The company entered an agreement intended to prevent facilities from excluding potential donors on that basis.

  Aftermath

  The two reported cases were resolved through the agreement.

  Source

• 2022

  Renaming Adopt-A-Patient as Plasma P.A.L.S.Strategy

  Background

  CSL Plasma used patient stories and donor engagement to explain the need for plasma-derived therapies and encourage donation.

  Action taken

  The company changed the program name to Plasma P.A.L.S., short for Plasma Patients And Life-Savers.

  Aftermath

  The renamed program continued as a donor and patient-awareness initiative.

  Source

• 2022.03.10

  Reported2022.03.10

  FDA approves the Rika plasma collection system[3]FDA 批准 Rika 血浆采集系统medscape.com

  The US Food and Drug Administration approved the Rika plasma collection device, developed jointly by Terumo Blood and Cell Technologies and CSL Plasma.

Read more

1. 1CSL Plasmaen.wikipedia.org
2. 2CSL Plasma official websitecslplasma.com
3. 3FDA 批准 Rika 血浆采集系统medscape.com